1. Introduction {#sec1}
===============

Friedenstein was the first to identify that single cell suspensions of bone marrow (BM) stroma could generate colonies of adherent fibroblast-like cells *in vitro* ([@bib28]). These colony-forming unit fibroblasts (CFU-Fs) were found to be capable of osteogenic differentiation and provided the first evidence that clonogenic stem cell precursors existed of the bone lineage ([@bib28], [@bib29]). Later these stromal cells were classified as stem cells, since single cells could transdifferentiate into multi-lineage cells of bone and osteogenic tissue ([@bib27]). Their eventual capability of generating the osteogenic, chondrogenic and adipogenic mesenchymal lineages meant they were then given the title of mesenchymal stem cells ([@bib10], [Fig. 1](#fig1){ref-type="fig"}). It was also shown that whilst they cannot make hematopoietic stem cells (HSCs), they do physically support them and promote their differentiation ([@bib19], [@bib67]). Interestingly, Caplan discussed the concept of cell transplantation therapy using MSCs therapeutically, but as a source of bone and connective tissue ([@bib10]). This became more pertinent when it was shown that MSCs only express the class I major histocompatibility complex (MHC-1) but not class II or co-stimulatory molecules such as CD40, CD80 and CD86 making them less likely to raise an immune response ([@bib51]). It has also been suggested that due to their limited pluripotent potential, MSCs should be re-named and termed "mesenchymal stromal cells" to avoid the excessive promotion of their stem cell potential ([@bib40], [@bib68]). Therefore, in this review the abbreviation MSC is referred to as mesenchymal stromal cells (MSCs).Fig. 1Differentiation of MSCs based on [@bib10]. MSCs have the capacity to differentiate into osteogenic, chondrogenic and adipogenic mesenchymal lineages.Fig. 1

1.1. MSCs and their origins {#sec1.1}
---------------------------

MSCs are known to be present in virtually all postnatal organs and tissues including heart, lung umbilical cord, peripheral blood, adipose tissue, muscle, cartilage, synovium, dental pulp, BM, tonsil, placenta, thymus and olfactory mucosa (OM) ([@bib16], [@bib49]; [@bib56], [@bib93], [@bib76]). However, whether they permanently reside in such tissues, or can circulate in the blood or even exist in perivascular spaces to reach different tissues is still not known ([@bib68]). By definition MSCs must i) adhere to plastic, ii) express specific cell surface markers and iii) differentiate in a multipotential manner along the osteogenic, chondrogenic, and adipogenic lineages ([@bib23]). A panel of markers are used to define MSCs including CD73 (ecto-5′nucleotidase) CD90 (Thy-1), CD105 (endoglin), CD166 (ALCAM), CD271 (p75NFGR/NTR), CD44 and STRO-1. However, none of these are specific and will also label a range of other cell types including endothelial cells, epithelial cells, fibroblasts, T cells and certain neural cell types ([@bib49], [@bib93]). MSCs also lack expression of CD34 (hematopoietic progenitor and endothelial cell marker), CD45 (pan-leukocyte marker), CD11b or CD14 (monocyte and macrophage markers), CD19 or CD79a (B cell markers), and HLA-DR (marker of stimulated MSCs) ([@bib63]). Initially their purification from BM was carried out by differential adherence to plastic since only the MSCs from stroma will adhere. However, there are now specific isolation kits available based on cell surface antibodies and magnetic selection which can be used to highly enrich for MSCs from a variety of different tissue sources, including BM. To add to the complexity, MSCs share cell-surface markers and localisation with pericytes, making their true classification and distinction even more complex ([@bib14]). Importantly, in the context of their therapeutic potential, these cells are widely available, have a high capacity to self-renew and are easily propagated in culture in substantial enough numbers. However the lack of standardised protocols for their expansion and isolation makes results difficult to interpret ([@bib68]).

1.2. MSCs from the human olfactory mucosa {#sec1.2}
-----------------------------------------

The uniquely regenerative properties of the olfactory system ([@bib35]) has meant that this tissue has gained much interest for the transplant mediated repair of the CNS ([@bib6], [@bib55], [@bib109], [@bib80]). Some of the transplantation studies have incorporated the use of the entire OM, while others have used the purified glial cell population, known as olfactory ensheathing cells ([@bib53], [@bib74]). We undertook a study to identify the stem cell population(s) from this tissue, since many researchers were already transplanting cells from OM into patients ([@bib54], [@bib57], [@bib30]). We identified MSC-like cells from the lamina propria of the human OM using CD271 purification and selection, which we termed OM-MSCs ([@bib56], [@bib43]). Detailed comparison was made with classical BM-derived MSCs which were isolated and maintained using identical methods and culture conditions ([@bib56], [@bib43]). We demonstrated that the OM-MSCs adhered to plastic, expressed classical markers and differentiated into bone and fat lineages in a similar manner to BM-MSCs. Furthermore, using a micro (mi)RNA array we showed that they were 64% homologous with a similar core subset of miRNAs ([@bib76]). We and others have also shown that while they were identical in their expression of a panel of CD markers, a greater proportion of OM-MSCs expressed nestin immunoreactivity; 100% of OM-MSCs express nestin compared to around 50% of BM-MSCs ([@bib55], [@bib43], [@bib18], [Fig. 2](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). The relevance of nestin-positive MSCs within the BM is now being evaluated by researchers. Nestin is a class VI intermediate filament protein which was originally identified as a stem cell marker for neuroepithelial cells ([@bib52]), although, it has been reported to label a range of cells from neural stem cells, fibroblasts and reactive glia ([@bib47], [@bib106], [@bib93]). [Table 1](#tbl1){ref-type="table"} summarises the comparative differences reported to date on OM-MSCs and BM-MSCs. Since OM-MSCs have only recently been identified, very few direct comparisons of their biological properties to BM-MSCs have been reported. Although, we have directly compared the two types of MSCs abilty to promote CNS myelination *in vitro* in the table, comparative data on myelination potential *in vivo* is limited. BM-MSCs have been shown to increase the number of oligodendrocytes, and enhance remyelination in EAE but similar data for OM-MSCs has not been published (see review of [@bib105]).Fig. 2Differential expression of nestin on OM-MSCs and BM-MSCs (nestin stained green; nuclei stained blue DAPI). Scale bar represents 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2Table 1Comparison of biological properties of olfactory mucosal- and bone marrow-derived MSCs.Table 1CharacteristicsOM-MSCsBM-MSCsReference**Marker expression**Express most classical MSC markers with difference reported only in:Nestin++++[@bib18], [@bib56], [@bib20], [@bib43], [@bib77]CD271++[@bib56], [@bib43]CD200, CD146−+[@bib18], [@bib90]**Micro RNA expression**miR-differentially expressed:[@bib76], [@bib101]140-5p; 10b-5p; 335-5p; 3665; 3188; 2861; 4281; 762; 874; 1915; 638; 424-5p; 140-5p; 224-5p; 140-3p; 939; 1225-5p.−+4291; 20a-5p; 25-3p; 106b-5p; 301a-3p; 195-5p; 497-5p; 93-5p; 3529-3p; 146a-5p+−**Gene expression**Nestin, CXCL12, CD90, S100A4, CD40++++[@bib18], [@bib43]; [@bib76][@bib90]CD73++++[@bib43]**Chemokines**CXCL12++++[@bib76]IL-6, IL-8, CCL2, IL-10, TGF-β++++[@bib76][@bib77]**Biological properties**Clonal efficiency, Proliferation+++−[@bib18], [@bib56]Osteogenesis, Adipogenesis++++[@bib18], [@bib56], [@bib90]Chondrogenesis−+++[@bib18], [@bib56], [@bib90]T-cell proliferation−−−−[@bib20], [@bib77]CNS Myelination (*in vitro*)++++/−[@bib56]; [@bib76]

1.3. Nestin-positive OM- and BM-MSCs {#sec1.3}
------------------------------------

Interestingly, a subpopulation of BM-MSCs have also been reported to express nestin ([@bib100], [@bib91]) and more detailed studies demonstrated that the nestin-positive MSCs are similar to early progenitor cells that are able to self-renew and differentiate into bone, fat and adipose ([@bib62]). These early progenitors have been hypothesised to be "mesodermal progenitor cells" or MPCs by other researchers ([@bib71] [@bib68]). The nestin-positive MSCs have been shown to co-localize with HSCs supporting their maintenance and homing ([@bib1]). Using transgenic mice that express the regulatory elements of the nestin-promotor (Nes-GFP) it was demonstrated that the nestin-positive MSC subpopulation originate from the neural crest and have special HSC niche functions, while the nestin-negative MSCs originate from the mesoderm and give rise to bone and cartilage ([@bib41]). Other epithelial tissues have also been suggested to contain neural crest derived mesenchymal progenitors including the human oral mucosa ([@bib17]), oral gingivae ([@bib94]), dental pulp tissue ([@bib87]) and airway epithelium ([@bib66]). Furthermore, nestin-positive MSCs were identified in airway epithelium within the perivascular areas and in connective tissue that is in close proximity to the airway epithelium ([@bib66]). These authors suggest that these MSCs circulate in the bloodstream, transmigrate through blood vessels and localize in the epithelium to participate in its turnover by being able to generate several different types of lung tissues. This could be a general feature of many different types of mucosa that exist throughout the body, where rapid turnover of cells is required after damage or during normal cell turnover. The importance of isolating nestin-positive neural crest derived MSCs for therapy over nestin-negative MSCs is not yet fully known. Moreover, the various subtypes of MSCs that make up the BM niche (illustrated in [Fig. 3)](#fig3){ref-type="fig"} have been mainly identified from rodent studies, and it is yet not known if similar cells exist in the human BM; although several recent reports have shown that the human BM niche contains nestin-positive MSCs ([@bib14], [@bib59], [@bib68], [@bib99]). These data corroborate our own published results which demonstrate that around 50% of purified BM-MSC express nestin immunoreactivity ([@bib43]).Fig. 3Schematic illustrating the various cell types in the rodent bone marrow niche including the range of cells secreting CXCL12 based on [@bib9].Fig. 3

We have shown that OM-MSCs, which are 100% nestin-positive better promoted *in vitro* CNS myelination when compared to BM-MSCs ([@bib56]) and that they also moved microglia to an anti-inflammatory phenotype, which correlated with their secretion of less pro-inflammatory cytokines ([@bib76]). In addition, others have shown different differentiation capabilities of nestin-positive neural crest derived MSCs, and have shown that they too have beneficial immunoregulatory function over immune cells when compared to mesodermal derived MSCs ([@bib94]). Therefore, it may be that there exists a subpopulation of neural crest derived MSCs in a variety of different tissues that are more suited to regenerative medicine.

1.4. The role of CXCL12 in the bone marrow niche {#sec1.4}
------------------------------------------------

The BM contains many cell types including HSCs, endothelial cells, osteoblasts, osteoprogenitors, chemokine (C--X--C motif) ligand 12 (CXCL12)-abundant reticular (CAR) cells and nestin+ NG2+ MSCs (which have been classified primarily based on the availability of a specific Cre-recombinase mouse or related reporter mouse which include *Lepr*-Cre ([@bib21]), *Prx1*-Cre ([@bib36]), *Nestin*-Cre ([@bib41], [@bib62]), CXCL12-GFP ([@bib82] [@bib79]). Cells were thus identified as nestin-GFP^dim^ and nestin-GFP^bright^ in one tracing experiment ([@bib1]) and nestin-LepR+ MSCs from a different reporter mouse. Moreover, definition of these various cell types does not exclude overlapping phenotype between each of these classified populations and so none of the defined cell types are exclusive from each other ([@bib39], [@bib13], [@bib21], [@bib36], [@bib79]). It is well understood that CXCL12 (stromal cell-derived factor-1) plays an important role within the human and rodent BM in controlling HSC and progenitor function ([@bib41], [@bib99]). Our own investigations have also revealed an important role for CXCL12 in human OM-MSC biology. OM-MSCs under the regulation of miR140-5p secrete more CXCL12 than BM-MSCs which is responsible for promoting rat CNS myelination *in vitro* to a greater extent than BM-MSCs ([@bib56], [@bib76]). In the BM, CXCL12 has a range of HSC regulatory functions from retention (blocking their differentiation and migration) to quiescence and repopulation activity ([@bib36], [@bib99]). BM-MSCs take part in the host defence by rapidly releasing CXCL12 into the circulation, which results in the mobilisation of progenitor cells ([@bib48], [@bib70]).

In the mouse BM three perivascular stromal cell populations that express high levels of CXCL12 have been identified: CXCL12-abundant reticular (CAR) cells, nestin-GFP+ stromal cells, and lepR+ stromal cells ([Fig. 3](#fig3){ref-type="fig"}). These stromal cell populations are defined by transgene expression using defined stromal-specific promoters, and as discussed above, it is likely that there is considerable overlap ([@bib3]). Other cells within the BM have been shown to secrete CXCL12 including, osteoblasts, and endothelial cells ([@bib21], [@bib79]). However, more recent detailed analysis using cell type specific promoters to knock out CXCL12 expression has shown that HSC maintenance and mobilisation was dependent upon nestin-positive mesenchymal progenitors ([@bib36]). Indeed deletion of nestin positive MSCs from the bone marrow has been shown to cause a dramatic expansion of HSCs due to a reduction in CXCL12 levels ([@bib4]). What this data highlights is an important role for CXCL12 secretion by nestin-positive MSCs and that such MSCs are central participants in HSC regulation.

It is also thought that within the BM microenvironment populations of cells exist which have differing roles in regulating the biology of HSCs ([@bib9], [@bib13]). The endosteal niche is mainly composed of osteoblasts, osteoclasts, adipocytes, CAR cells, stromal cells, nestin+ MSCs, which together maintain HSCs in a quiescent state. In contrast, the vascular niche which is located near to BM sinusoid vessels is composed of perivascular (nestin+) stromal cells, CAR cells and the peripheral glia, Schwann cells. The former two cell types favouring HSC activation and recruitment, with the latter involved in HSC maintenance. Interestingly, there has been a report to suggest that human OM-MSCs can also promote the *in vitro* survival, proliferation and differentiation of human HSCs ([@bib72]). Thus it is possible then that nestin+ MSCs from the OM are similar to these nestin+ MSCs from the BM or are in fact the same neural crest derived source of MSCs. Further experiments, including fate mapping are required to fully elucidate whether OM-MSCs are indeed neural crest derived although it is tempting to speculate that they are, as it has been shown using reporter mice, that olfactory ensheathing cells ([@bib7]), olfactory receptor neurons, sustentacular cells and the basal stem cells from the olfactory epithelium after injury, originate from the neural crest ([@bib84]).

1.5. MSCs for the treatment of CNS disease/injury {#sec1.5}
-------------------------------------------------

BM-MSCs have long been considered as candidates for the transplant-mediated repair of the injured or diseased CNS. They have already been evaluated in a number of clinical trials for the treatment of a range of CNS disorders including amyotrophic lateral sclerosis ([@bib78], [@bib104], [@bib61] [@bib65]); progressive supranuclear palsy ([@bib32]); cerebral palsy in children ([@bib88]; ischaemic heart failure ([@bib58], [@bib75]); myocardial infarction ([@bib37]); knee osteoarthritis ([@bib86]); acute respiratory distress syndrome ([@bib92]) and Crohn\'s disease ([@bib24]). However most of these studies are phase I and have only shown safety of administration rather than efficacy.

Since MSCs are thought to have an immunomodulatory role, they have also been proposed for the treatment of the immune mediated demyelinating disease, Multiple Sclerosis (MS). In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, MSC transplantation has been shown to have promising beneficial effects, using both syngeneic cells ([@bib31], [@bib45]) as well as human cells ([@bib5], [@bib73]). These include a reduction in demyelination, axonal loss, leucocyte infiltration, inhibition of T cell proliferation, and macrophage/microglia activation. The beneficial effects of BM-MSC transplantation in EAE are generally attributed to immunomodulatory effects in the periphery, although they may also migrate into the CNS to secrete soluble neuroprotective factors that support endogenous tissue repair and remyelination ([@bib5], [@bib26], [@bib98]). Culturing BM-MSCs with microglia has indicated that they promote a switch in LPS-activated microglia from a detrimental phenotype to one more beneficial ([@bib33]). Moreover, promising effects have been seen in human trials of autologous transplantation of BM-MSCs in secondary progressive patients illustrating their safety. There is also evidence of neuroprotection from structural, functional, and physiological improvement which strongly supports their future use as treatment in MS ([@bib8], [@bib12], [@bib38], [@bib85]; [@bib108]).

While it has been known for numerous years that the human olfactory tissue contains multipotent stem cells which were typically from the basal layer in the epithelium, or from the olfactory bulb ([@bib103] [@bib83] [@bib102], [@bib64]; [@bib96]), it was only recently that mesenchymal like stromal cells were identified from the lamina propria of the OM ([@bib97], [@bib18]), and since then OM derived MSCs have only been described in a handful of reports detailing their use in tissue repair. For example, a study was carried out using human MSCs from the OM in a mouse model of early onset sensorineural hearing loss ([@bib69]). Here olfactory MSCs, prepared as described by [@bib18], were injected into the cochlea of A/J mice which exhibit early-onset progressive sensorineural hearing loss. OM-MSC transplantation was seen to prevent hearing loss as assessed by response to both click and pure tone stimuli suggesting they protect against loss of auditory function. Other studies have been reported on the repair potential of OM-MSCs using mice with hippocampal lesions created by the injection of a NMDA agonist. In these mice, transplantation of OM-MSCs restored learning and memory using behavioural testing when compared to non-transplanted control mice ([@bib81]). A recent study using mouse derived OM-MSCs also demonstrated that they could suppress arthritis onset in a mouse model of collagen-induced arthritis ([@bib77]).

Furthermore, it is possible that in experiments which use dissociated olfactory mucosa cells, OM-MSCs may be present in the heterogeneous cell mix ([@bib54], [@bib107] [@bib64], [@bib11], [@bib34], [@bib42], [@bib89]). However, there is no detailed analysis of the cellular composition of these cellular mixes or which cell type(s) dominate or in fact which cell type has reparative properties. Indeed a spinal cord injured patient who received a transplant of un-purified olfactory mucosa was found to develop an intramedullary spinal cord mass 8 years post-surgery, composed of cysts lined with respiratory epithelium ([@bib22]). Therefore, the use of un-purified olfactory mucosal cells cannot be directly compared to purified OM-MSCs and indeed highlights the importance of transplanting cells which are fully characterised. In terms of therapeutic paradigms it is vital that any cell type that is to be transplanted is fully characterised. Unfortunately, due to the technical variability in harvesting and growing cells from both BM and OM it is difficult to compare data across experiments. However, from the limited studies and our own data, which demonstrates OM-MSCs promote rat CNS myelination *in vitro* ([@bib55], [@bib76]) and *in vivo* (Lindsay et al., submitted), we would postulate they may be an alternative candidate for the treatment in MS or other demyelinating diseases/injuries. Similarly they may be advantageous where neuroprotection or neurite outgrowth is important for repair eg retinitis pigmentosa, age-related macular degeneration, ALS, and stroke. The identification that OM-MSCs secrete higher levels of the chemokine CXCL12 than BM-MSCs ([@bib76]), which we and others have shown to be important in augmenting endogenous myelination ([@bib60], [@bib56], [@bib76] [@bib95]) also adds to the desirability as a candidate cell for transplantation. Lastly as MSCs are known to home to damaged tissue ([@bib50], [@bib25]) and secrete a plethora of pro-repair factors, their use as a treatment is more beneficial than application of a chemokine alone ([@bib2], [@bib44], [@bib50]).

In conclusion, we feel that nestin-positive OM-MSCs may be derived from the neural crest, and are an easily accessible source of cells which may be therapeutically advantageous over BM-MSCs for the treatment of demyelinating conditions such as MS.
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